(AOF) – Bristol Myers Squibb is expected to rise in pre-market on Wall Street after forgetting better than expected results for the fourth quarter. The American pharmaceutical group posted adjusted earnings per share of $1.70 versus $1.53 expected, for revenue up 1% to $11.48 billion, versus $11.19 billion expected. BMS expects revenue growth of between 1% and 5% in 2024 with earnings per share of between $7.10 and $7.40.
The laboratory owes this success to sales of its drugs against anemia, Revlimid which collected 1.45 billion dollars, and Reblozyl which brought in 320 million dollars during the quarter, while analysts expected 1.27 billion and $280 million, respectively.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
